CTKB (STOCKS)
Cytek Biosciences, Inc. Common Stock
$3.930000
-0.030000 (-0.76%)
Prev close: $3.960000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Wen Bin Jiang
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $506.89M
- Employees
- 688
- P/E (TTM)
- -6.81
- P/B (TTM)
- 1.56
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
4
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.15 | $-0.10 | -0.0514 | -52.13% |
|
Dec 2025 (Q4)
|
$-0.04 | $-0.02 | -0.0196 | -96.08% |
|
Sep 2025 (Q3)
|
$-0.04 | $-0.05 | +0.0136 | +25.37% |
|
Jun 2025 (Q2)
|
$-0.04 | $-0.07 | +0.0314 | +43.98% |
Financial Statements
| Revenues | $204.17M |
| Benefits Costs and Expenses | $178.61M |
| Cost Of Revenue | $98.61M |
| Costs And Expenses | $241.21M |
| Gross Profit | $105.56M |
| Nonoperating Income/Loss | $7.93M |
| Operating Expenses | $149.43M |
| Research and Development | $36.35M |
| Other Operating Expenses | $113.08M |
| Operating Income/Loss | -$43.87M |
| Income/Loss From Continuing Operations After Tax | -$74.00M |
| Income/Loss From Continuing Operations Before Tax | $25.56M |
| Income Tax Expense/Benefit | $38.06M |
| Income Tax Expense/Benefit, Deferred | $33.71M |
| Net Income/Loss | -$74.00M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$74.00M |
| Net Income/Loss Available To Common Stockholders, Basic | -$74.00M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Average Shares | 383,328,709 |
| Diluted Average Shares | 383,328,709 |
| Assets | $449.11M |
| Current Assets | $379.30M |
| Inventory | $49.79M |
| Other Current Assets | $329.51M |
| Noncurrent Assets | $69.81M |
| Fixed Assets | $20.47M |
| Intangible Assets | $15.70M |
| Other Non-current Assets | $33.64M |
| Liabilities | $121.47M |
| Current Liabilities | $80.94M |
| Noncurrent Liabilities | $40.53M |
| Equity | $327.64M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $327.64M |
| Liabilities And Equity | $449.11M |
| Net Cash Flow From Operating Activities | -$7.30M |
| Net Cash Flow From Operating Activities, Continuing | -$7.30M |
| Net Cash Flow From Investing Activities | -$26.41M |
| Net Cash Flow From Investing Activities, Continuing | -$26.41M |
| Net Cash Flow From Financing Activities | $2.09M |
| Net Cash Flow From Financing Activities, Continuing | $2.09M |
| Exchange Gains/Losses | $1.98M |
| Net Cash Flow | -$29.63M |
| Net Cash Flow, Continuing | -$31.62M |
| Comprehensive Income/Loss | -$71.60M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$71.03M |
| Other Comprehensive Income/Loss | -$16.46M |